Moderna's late-stage cancer vaccine data lifts shares, validating diversification strategy

Moderna's stock jumped to multi-year highs after the company released late-stage data for its cancer vaccine, providing evidence that its strategy to expand beyond infectious disease work is paying off. The results appear to have eased investor doubts about the company's future prospects.